Synergy Pharmaceuticals Inc.

Canaccord Genuity acts as Joint Book-Running Manager for US$125 million Overnight Offering for Synergy Pharmaceuticals Inc.

Canaccord Genuity is pleased to announce that on February 1, 2017, it underwrote an overnight offering of common stock for Synergy Pharmaceuticals Inc. (Nasdaq: SGYP). The Company issued a total of 20,325,204 shares at a price of US$6.15 per common share. Canaccord Genuity acted as joint book-running manager for the offering.

Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. Synergy has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders. Synergy discovered, is developing and controls 100% worldwide rights to its proprietary uroguanylin analog platform which includes one commercial product TRULANCE (plecanatide) and a second lead product candidate - dolcanatide.